Laser Interstitial Thermal Therapy in Grade 2/3 IDH1/2 Mutant Gliomas: A Preliminary Report and Literature Review

Gabrielle W. Johnson; Rowland H. Han; Matthew D. Smyth; Eric C. Leuthardt; Albert H. Kim

doi:10.3390/curroncol29040209

Laser Interstitial Thermal Therapy in Grade 2/3 IDH1/2 Mutant Gliomas: A Preliminary Report and Literature Review

Gabrielle W. Johnson, Rowland H. Han, Matthew D. Smyth, Eric C. Leuthardt, Albert H. Kim

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Laser interstitial thermal therapy (LITT) has become an increasingly utilized alternative to surgical resection for the treatment of glioma in patients. However, treatment outcomes in isocitrate dehydrogenase 1 and 2 (IDH1/2) mutant glioma, specifically, have not been reported. The objective of this study was to characterize a single institution’s cohort of IDH1/2 mutant grade 2/3 glioma patients treated with LITT. We collected data on patient presentation, radiographic features, tumor molecular profile, complications, and outcomes. We calculated progression-free survival (PFS) and tested factors for significant association with longer PFS. Overall, 22.7% of our cohort experienced progression at a median follow up of 1.8 years. The three-and five-year estimates of PFS were 72.5% and 54.4%, respectively. This is the first study to characterize outcomes in patients with IDH1/2 mutant glioma after LITT. Our results suggest that LITT is an effective treatment option for IDH1/2 mutant glioma.

Original language	English
Pages (from-to)	2550-2563
Number of pages	14
Journal	Current Oncology
Volume	29
Issue number	4
DOIs	https://doi.org/10.3390/curroncol29040209
State	Published - Apr 2022

Keywords

IDH1 mutation
IDH2 mutation
astrocytoma
glioma
laser interstitial thermal therapy
oligodendroglioma

Access to Document

10.3390/curroncol29040209

Cite this

@article{ea4a641cb7f24f54bef56dbf5af95904,

title = "Laser Interstitial Thermal Therapy in Grade 2/3 IDH1/2 Mutant Gliomas: A Preliminary Report and Literature Review",

abstract = "Laser interstitial thermal therapy (LITT) has become an increasingly utilized alternative to surgical resection for the treatment of glioma in patients. However, treatment outcomes in isocitrate dehydrogenase 1 and 2 (IDH1/2) mutant glioma, specifically, have not been reported. The objective of this study was to characterize a single institution{\textquoteright}s cohort of IDH1/2 mutant grade 2/3 glioma patients treated with LITT. We collected data on patient presentation, radiographic features, tumor molecular profile, complications, and outcomes. We calculated progression-free survival (PFS) and tested factors for significant association with longer PFS. Overall, 22.7% of our cohort experienced progression at a median follow up of 1.8 years. The three-and five-year estimates of PFS were 72.5% and 54.4%, respectively. This is the first study to characterize outcomes in patients with IDH1/2 mutant glioma after LITT. Our results suggest that LITT is an effective treatment option for IDH1/2 mutant glioma.",

keywords = "IDH1 mutation, IDH2 mutation, astrocytoma, glioma, laser interstitial thermal therapy, oligodendroglioma",

author = "Johnson, {Gabrielle W.} and Han, {Rowland H.} and Smyth, {Matthew D.} and Leuthardt, {Eric C.} and Kim, {Albert H.}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = apr,

doi = "10.3390/curroncol29040209",

language = "English",

volume = "29",

pages = "2550--2563",

journal = "Current Oncology",

issn = "1198-0052",

number = "4",

}

TY - JOUR

T1 - Laser Interstitial Thermal Therapy in Grade 2/3 IDH1/2 Mutant Gliomas

T2 - A Preliminary Report and Literature Review

AU - Johnson, Gabrielle W.

AU - Han, Rowland H.

AU - Smyth, Matthew D.

AU - Leuthardt, Eric C.

AU - Kim, Albert H.

PY - 2022/4

Y1 - 2022/4

N2 - Laser interstitial thermal therapy (LITT) has become an increasingly utilized alternative to surgical resection for the treatment of glioma in patients. However, treatment outcomes in isocitrate dehydrogenase 1 and 2 (IDH1/2) mutant glioma, specifically, have not been reported. The objective of this study was to characterize a single institution’s cohort of IDH1/2 mutant grade 2/3 glioma patients treated with LITT. We collected data on patient presentation, radiographic features, tumor molecular profile, complications, and outcomes. We calculated progression-free survival (PFS) and tested factors for significant association with longer PFS. Overall, 22.7% of our cohort experienced progression at a median follow up of 1.8 years. The three-and five-year estimates of PFS were 72.5% and 54.4%, respectively. This is the first study to characterize outcomes in patients with IDH1/2 mutant glioma after LITT. Our results suggest that LITT is an effective treatment option for IDH1/2 mutant glioma.

AB - Laser interstitial thermal therapy (LITT) has become an increasingly utilized alternative to surgical resection for the treatment of glioma in patients. However, treatment outcomes in isocitrate dehydrogenase 1 and 2 (IDH1/2) mutant glioma, specifically, have not been reported. The objective of this study was to characterize a single institution’s cohort of IDH1/2 mutant grade 2/3 glioma patients treated with LITT. We collected data on patient presentation, radiographic features, tumor molecular profile, complications, and outcomes. We calculated progression-free survival (PFS) and tested factors for significant association with longer PFS. Overall, 22.7% of our cohort experienced progression at a median follow up of 1.8 years. The three-and five-year estimates of PFS were 72.5% and 54.4%, respectively. This is the first study to characterize outcomes in patients with IDH1/2 mutant glioma after LITT. Our results suggest that LITT is an effective treatment option for IDH1/2 mutant glioma.

KW - IDH1 mutation

KW - IDH2 mutation

KW - astrocytoma

KW - glioma

KW - laser interstitial thermal therapy

KW - oligodendroglioma

UR - http://www.scopus.com/inward/record.url?scp=85128621339&partnerID=8YFLogxK

U2 - 10.3390/curroncol29040209

DO - 10.3390/curroncol29040209

M3 - Article

C2 - 35448183

AN - SCOPUS:85128621339

SN - 1198-0052

VL - 29

SP - 2550

EP - 2563

JO - Current Oncology

JF - Current Oncology

IS - 4

ER -

Laser Interstitial Thermal Therapy in Grade 2/3 IDH1/2 Mutant Gliomas: A Preliminary Report and Literature Review

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this